FITC Conjugated, Anti-CD263 / TRAIL-R3 Monoclonal Antibody (Clone:TRAIL-R3-02)
Figure 1: Surface staining of CD263-transfectants (red) using anti-CD263 (TRAIL-R3-02) FITC.
Roll over image to zoom in
Shipping Info:
For estimated delivery dates, please contact us at [email protected]
| Amount : | 0.1 mg |
| Isotype : | Mouse IgG1 |
| Storage condition : | Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. |
TRAIL-R3 (CD263, TR3, DcR1, LIT, TRID), expressed mainly on neutrophils, belongs to receptors of TRAIL, a TNF-like membrane cytotoxic protein that induces apoptosis in many tumour cells, but not in normal cells. TRAIL-R3, however, is a GPI-anchored protein that lacks cytoplasmic death domain, thus it is unable to induce apoptosis and serves as a negative regulator of apoptotic signaling by competing for binding of TRAIL with death receptor 5 (DR5).
| Subcellular location: | Cell membrane |
| Post transnational modification: | N-glycosylated and O-glycosylated. |
| Tissue Specificity: | Higher expression in normal tissues than in tumor cell lines. Highly expressed in peripheral blood lymphocytes, spleen, skeletal muscle, placenta, lung and heart. |
| BioGrid: | 114322. 63 interactions. |
|
There are currently no product reviews
|
.png "ACE2/HEK293 Stable Cell Line")
